

Mark Ballantyne

Partner



mballantyne@cooley.com

+1 703 456 8084

Reston

Public Companies

Capital Markets

Life Sciences

Technology

CooleyREG

Mark Ballantyne focuses his practice on representing IPO ready and publicly traded life sciences and technology companies, as well as underwriters.

Mark has provided strategic advice to numerous companies in connection with IPOs, capital markets transactions and Exchange Act reporting. Mark has recently worked on completed securities offerings by companies including 2U, Aclaris, Appian, BigCommerce, Cardlytics, ChannelAdvisor, Clearside, Dova Pharmaceuticals, GlycoMimetics, KemPharm, Legend Biotech, Luna Innovations, Millennial Media, ObsEva, Orphazyme, Senseonics and Verrica Pharmaceuticals.

Mark has also represented various investment banks in capital markets transactions, including BofA Securities, Barclays, Canaccord, Cantor, Cowen, Citigroup, Credit Suisse, Deutsche Bank, Evercore, Goldman Sachs, H.C. Wainwright, Jefferies, J.P. Morgan, Morgan Stanley, Needham, Oppenheimer, Piper Sandler, Raymond James, Stifel, SVB Leerink, UBS, Wedbush, Wells Fargo and William Blair.

Representative company-side and underwriter-side public offerings:

- BigCommerce Holdings – \$216.5 million IPO
- Cardlytics – \$91.6 million following on offering and \$200 million convertible notes offering
- Legend Biotech – \$423.8 million IPO
- Orphazyme – \$83.8 million IPO
- LogicBio Therapeutics – \$80.5 million IPO
- Aclaris Therapeutics – \$92.9 million follow-on offering
- KemPharm – \$64.4 million IPO and \$25 million follow-on offering
- Aldeyra Therapeutics – \$72.2 million follow-on offering
- Appian – aggregate \$147.3 for multiple follow-on offerings
- Translate Bio – \$121.6 million IPO
- Verrica Pharmaceuticals – \$75 million IPO
- Clearside Biomedical – \$85 million follow-on offering
- Dova Pharmaceuticals – \$80 million follow-on offering
- Vascular Biogenics – \$18.75 million follow-on offering

- Apellis Pharmaceuticals – \$150 million IPO
- Senseonics Holdings – \$49.1 million IPO
- ObsEva – \$111.3 million IPO
GlycoMimetics – \$56 million IPO
- ChannelAdvisor – \$92.6 million IPO
- 2U – \$119.3 million IPO
- Gladstone Land – \$50 million IPO
- MongoDB – \$192 million IPO
- Valeritas – \$52.5 million IPO
- Amedica – \$20.1 million IPO
- T2 Biosystems – \$65.8 million IPO

Mark received a recognition from Best Lawyers as Ones to Watch in Securities/Capital Markets Law and Venture Capital Law.

Education

University of Richmond School of Law
JD, 2012

Wake Forest University
BA, 2008

Admissions & Credentials

Virginia

Court Admissions

Virginia Supreme Court

Rankings & Accolades

Best Lawyers: Ones to Watch - Securities/Capital Markets Law and Venture Capital Law (2021)